Assay News and Research

RSS

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

A new study suggests that modified natural killer cells, which express a chimeric antigen receptor using S309 antibody, can bind to and inactivate SARS-CoV-2 spike protein in vitro.

18 Jan 2021

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

An interesting new preprint research paper that was posted on the bioRxiv* server recently describes the use of rigid monoclonal antibodies (mAbs) in contrast to flexible mAbs, and how this affects the binding of multiple mAbs to the same antigen.

17 Jan 2021

A high-temperature tolerant SARS-CoV-2 derived immunogen as a potential vaccine candidate

There have been significant efforts worldwide to combat COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One prominent strategy has been to develop vaccines against the virus. Numerous vaccine candidates are under development, and a handful have now been approved for use by several countries.

17 Jan 2021

Research suggests St. John's Wort and Echinacea could protect against COVID-19

Researchers in Saudi Arabia have conducted a study demonstrating the antiviral effects of two medicinal herbs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jan 2021

IOF and IFCC review describes the current status of assays for reference bone turnover markers

Bone turnover markers (BTMs) in blood and urine are useful tools in monitoring osteoporosis treatment effects and may be useful for improving patient adherence.

16 Jan 2021

Research reveals new details into how myosin transduces energy

A team of biophysicists from the University of Massachusetts Amherst and Penn State College of Medicine set out to tackle the long-standing question about the nature of force generation by myosin, the molecular motor responsible for muscle contraction and many other cellular processes.

14 Jan 2021

New tests may help reveal the transcriptome of SARS-CoV-2 and predict disease course

As the COVID-19 pandemic continues to infect people in their hundreds of thousands around the world, a new study describes a panel of novel tests for genomic (g) and subgenomic (sg) mRNAs generated by SARS-CoV-2. Most assays in use at present are either qualitative or semi-quantitative, and cannot evaluate the transcription molecules in detail.

14 Jan 2021

Influenza drug enisamium a potential COVID-19 treatment

Researchers in Europe and the United States have demonstrated the potential of the influenza drug enisamium as a treatment for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Jan 2021

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

Researchers from the University of Cambridge and the Pirbright Institute in the UK have identified key genetic changes in SARS-CoV-2 that may be responsible for the virus’s jump from bats to humans. The team also determined which animals contain cellular receptors that allow the virus to enter cells more effectively, zoning in on potential animals that acted as an intermediary host in facilitating SARS-CoV-2’s zoonosis.

13 Jan 2021

Could fenofibrate be an effective antiviral against SARS-CoV-2?

The resurgence of COVID-19 pandemic, caused by the SARS-CoV-2, has led to renewed efforts to find effective antivirals, both newly developed or repurposed drugs. A study reports the efficacy of the cholesterol-reducing drug fenofibrate in reducing infection rates of SARS-CoV-2 in cultured cells.

13 Jan 2021

Axol Bioscience strengthens commercial leadership team with key appointments

Axol Bioscience today announced the appointment of Ross Wheatcroft as the Global Strategic Accounts Manager.

From Axol Bioscience Ltd 13 Jan 2021

Will the Pfizer–BioNTech vaccine be effective against the new N501Y SARS-CoV-2 variant?

Researchers from Pfizer and the University of Texas, USA, have presented evidence showing that people in a previously reported trial of the mRNA-based COVID-19 vaccine, BNT162b2 – commonly known as the Pfizer-BioNTech COVID-19 vaccine – had equivalent neutralizing titers to the N501 and Y501 viruses.

12 Jan 2021

Researchers develop saliva testing method for SARS-CoV-2 using robotic RNA extraction

Researchers have developed an automated method of RNA extraction from saliva samples to allow faster processing times and high test sensitivity. Saliva testing could be used as an alternative to swab testing for coronavirus disease 2019 (COVID-19) surveillance.

12 Jan 2021

SARS-CoV-2 exposure in England could be double reported seroprevalence

A new study that recently appeared on the preprint server medRxiv* makes use of a combined method to estimate population exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), taking into account the fact that patients who recover from the infection often do not have circulating antibodies against the virus.

11 Jan 2021

New test detects SARS-CoV-2 in less than 5 mins

A fast and accurate virus detection strategy is very crucial to reduce the rate of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19. The global scientific research community responded to this unprecedented demand in diagnostic testing by developing several detection platforms, the most sensitive of which detect the viral RNA.

10 Jan 2021

FDA alerts health care providers and clinical laboratory staff about SARS-CoV-2 viral mutation

The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus's genome assessed by that test.

8 Jan 2021

How do SARS-CoV-2 antibodies change over time in recovered patients?

Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.

8 Jan 2021

Researchers develop a low-cost, saliva-optimized RT-LAMP assay for faster detection of SARS-CoV-2

SARS-CoV-2 pandemic has highlighted the shortcomings in emergency response globally and has driven a massive demand for in vitro diagnostic testing technologies. In order to address these issues, researchers from the US recently used the new pH dye LAMPShade Violet (LSV) in RT-LAMP. LSV has better visual contrast between high and low pH and a stronger inflection point, both of which enable easy interpretation of results and reduces ambiguity.

8 Jan 2021

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

A new preprint research paper appearing on the medRxiv server describes a link between the persistence of neutralizing antibodies against the virus, disease severity, and specific COVID-19 symptoms.

7 Jan 2021

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

A recent study, currently available on the medRxiv* preprint server, is among the first to reveal the presence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in colostrum and to demonstrate elevated cytokine levels in colostrum from women exposed to the virus.

7 Jan 2021

Assay News and Research

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

A high-temperature tolerant SARS-CoV-2 derived immunogen as a potential vaccine candidate

Research suggests St. John's Wort and Echinacea could protect against COVID-19

IOF and IFCC review describes the current status of assays for reference bone turnover markers

Research reveals new details into how myosin transduces energy

New tests may help reveal the transcriptome of SARS-CoV-2 and predict disease course

Influenza drug enisamium a potential COVID-19 treatment

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

Could fenofibrate be an effective antiviral against SARS-CoV-2?

Axol Bioscience strengthens commercial leadership team with key appointments

Will the Pfizer–BioNTech vaccine be effective against the new N501Y SARS-CoV-2 variant?

Researchers develop saliva testing method for SARS-CoV-2 using robotic RNA extraction

SARS-CoV-2 exposure in England could be double reported seroprevalence

New test detects SARS-CoV-2 in less than 5 mins

FDA alerts health care providers and clinical laboratory staff about SARS-CoV-2 viral mutation

How do SARS-CoV-2 antibodies change over time in recovered patients?

Researchers develop a low-cost, saliva-optimized RT-LAMP assay for faster detection of SARS-CoV-2

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News